Furthermore, PD-L1 is a useful predictor of poor prognoses in patients with bone and soft tissue sarcomas, but is insufficient as a predictor of anti-PD-1 therapy efficacy44,52. This evidence concerns the gene CD274 and soft tissue sarcoma.